CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.
On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).
Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]
CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. 
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has contracted with the Cell Manipulation Core Facility at Dana-Farber Cancer Institute to 
On June 25, 2018, Bio-Techne announced it is acquiring Exosome Diagnostics for $250 million in cash and up to $325 million for achieving certain milestones. As exosome therapeutics and diagnostics have multiplied in number, a number of investors have placed big bets on this rapidly growing marketplace.
On July 2nd, 2018,